Dactinomycin

Actinomycin — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Dactinomycin is a drug in the Actinomycin class catalogued in DrugCentral. It was first approved by the FDA in 1964. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors and Protein Synthesis Inhibitors. DrugCentral lists 4 molecular targets, including GRB2, Grb2 and DDR2. Recorded indications include Ewing's sarcoma, Gestational trophoblastic neoplasia, Malignant tumor of testis and Nephroblastoma.

• Drug class: Actinomycin.
• Mechanism of action: Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors.
• Molecular targets: GRB2, Grb2, DDR2 and NGLY1 (4 listed in DrugCentral).
• Indications: Ewing's sarcoma, Gestational trophoblastic neoplasia, Malignant tumor of testis, Nephroblastoma and Rhabdomyosarcoma.
• ATC code: L01DA01 (Actinomycines).
• Molecular formula: C62H86N12O16; molecular weight 1255.44 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Ewing's sarcoma
• Gestational trophoblastic neoplasia
• Malignant tumor of testis
• Nephroblastoma
• Rhabdomyosarcoma

Off-label uses (2)

• Kaposi's sarcoma
• Ovarian Germ Cell Tumor Carcinoma

Contraindications (16)

• Acute infectious disease
• Anemia
• Aplastic anemia
• Ascites
• Bone marrow depression
• Breastfeeding (mother)
• Disease of liver
• Exposure to varicella
• Hepatic vein thrombosis
• Herpes zoster
• Leukopenia
• Liver function tests abnormal
• Neutropenic disorder
• Pregnancy, function
• Thrombocytopenic disorder
• Varicella-zoster virus infection

Mechanism & targets

• Mechanism of action (MoA): Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors
• Established pharmacologic class: Actinomycin

Molecular targets (4)

Target	Gene	Action	Activity
Growth factor receptor-bound protein 2	GRB2	unknown	IC50 5.30
Growth factor receptor-bound protein 2	Grb2	unknown	IC50 5.30
Discoidin domain-containing receptor 2	DDR2	unknown	IC50 5.05
Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase	NGLY1	unknown	Kd 4.05

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1964-12-10	FDA	—	RECORDATI RARE

ATC classification

ATC code	Therapeutic hierarchy
L01DA01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES › Actinomycines

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ovarian failure	530.5
Febrile neutropenia	427.8
Venoocclusive liver disease	375.9
Maternal exposure before pregnancy	367.1
Venoocclusive disease	297.8
Neutropenia	288.3
Off label use	287.9
Acute myeloid leukaemia	281.8
Second primary malignancy	237.7
Product use in unapproved indication	220.6
Disease progression	206.0
Drug resistance	201.0

Chemical structure

• Molecular formula: C₆₂H₈₆N₁₂O₁₆
• Molecular weight: 1255.44 g/mol
• CAS number: —
• InChIKey: RJURFGZVJUQBHK-IIXSONLDSA-N
• PubChem CID: 457193

CC(C)[C@H]1NC(=O)[C@@H](NC(=O)C2=C3N=C4C(OC3=C(C)C=C2)=C(C)C(=O)C(N)=C4C(=O)N[C@H]2[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]3CCCN3C(=O)[C@H](NC2=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dactinomycin used for?

DrugCentral lists the following indications for Dactinomycin: Ewing's sarcoma, Gestational trophoblastic neoplasia, Malignant tumor of testis, Nephroblastoma and Rhabdomyosarcoma.

How does Dactinomycin work?

Dactinomycin is classified as Nucleic Acid Synthesis Inhibitors and Protein Synthesis Inhibitors; its molecular targets in DrugCentral include GRB2, Grb2, DDR2 and NGLY1.

When was Dactinomycin first approved?

Dactinomycin was first approved by the FDA in 1964.

What drug class does Dactinomycin belong to?

Dactinomycin is in the Actinomycin class.

What is the chemical formula of Dactinomycin?

Dactinomycin has the molecular formula C62H86N12O16 and a molecular weight of 1255.44 g/mol.

Sources

• DrugCentral drug card 774 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1554 — compound record and bioactivity
• PubChem CID 457193 — chemical identifiers
• DrugBank DB00970 — drug record
• FDA UNII 1CC1JFE158 — substance identity
• DailyMed: FDA labels for Dactinomycin — current prescribing information (label search)
• UniProt P62993 (GRB2) — target protein
• UniProt Q16832 (DDR2) — target protein
• UniProt Q96IV0 (NGLY1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.